

522,421

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



24 JAN 2005

(43) International Publication Date  
5 February 2004 (05.02.2004)

PCT

(10) International Publication Number  
**WO 2004/010980 A1**

- (51) International Patent Classification<sup>7</sup>: **A61K 9/22**,  
31/47, A61P 9/10, 3/06
- (21) International Application Number:  
PCT/EP2003/008179
- (22) International Filing Date: 24 July 2003 (24.07.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
0217306.0 25 July 2002 (25.07.2002) GB
- (71) Applicant (*for all designated States except AT, US*): NO-  
VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel  
(CH).
- (71) Applicant (*for AT only*): NOVARTIS PHARMA GMBH  
[AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): MEYER, An-  
dreas [DE/DE]; Akazienweg 1, 79395 Neuenburg (DE).  
OGORKA, Jörg [DE/DE]; Im Steinbrunnen 19/3, 79585
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM,  
PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM,  
TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): Eurasian patent (AM, AZ,  
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,  
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,  
IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).
- Published:  
— with international search report  
— before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments
- For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: COMPOSITIONS COMPRISING HMG-COA REDUCTASE INHIBITOR

(57) Abstract: The present invention relates to pharmaceutical compositions for sustained release comprising as active ingredient an HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof, said composition comprising an inner phase (internal) and an outer phase (external), wherein at least the outer phase comprises at least one matrix former.



WO 2004/010980 A1